# Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens

> **NCT00419081** · PHASE2 · TERMINATED · sponsor: **BioCryst Pharmaceuticals** · enrollment: 100 (—)

## Conditions studied

- Leukemia
- Lymphoma

## Interventions

- **DRUG:** Forodesine Hydrochloride Sterile Solution, 5 mg/mL
- **DRUG:** Forodesine Hydrochloride Capsules (100 mg)

## Key facts

- **NCT ID:** NCT00419081
- **Lead sponsor:** BioCryst Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-07
- **Primary completion:** 2007-03
- **Final completion:** 2007-03
- **Target enrollment:** 100 (—)
- **Why stopped:** Issues with Manufacturing
- **Last updated:** 2012-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00419081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00419081, "Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT00419081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*